Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUE Vascular Graft for Hemodialysis Access
NCT04905511Phase 1Completed
- Sponsor
- Vascudyne
- Start
- May 2021
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Vascudyne. Primary endpoints: Safety, adverse events at 26 weeks and Patency at 26 weeks. Started May 2021; status: completed.
Beyond the preview
Go deeper on NCT04905511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905511.